Back to results
US 12,005,052 B2Granted
Topical roflumilast formulation having improved delivery and plasma half-life
AssigneeArcutis Biotherapeutics, Inc.
InventorDavid W. Osborne
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.
Claims9
A pharmaceutical composition for topical administration comprising:
- (i) roflumilast, wherein the roflumilast is in an amount of 0.05-1.0% w/w;
- (ii) water;
- (iii) diethylene glycol monoethyl ether;
- and
- (iv) an emulsifier blend comprising cetostearyl alcohol, dicetyl phosphate and ceteth-10 phosphate;
- wherein the plasma half-life of the roflumilast is between 3 and 5 days after topical administration of the composition.
3 more elements
A pharmaceutical composition for topical administration comprising:
- (i) roflumilast in an amount of 0.05-1.0% w/w;
- (ii) water qs ad 100% w/w;
- (iii) diethylene glycol monoethyl ether in an amount of 10-30% w/w;
- and
- (iv) an emulsifier blend comprising cetostearyl alcohol, dicetyl phosphate and ceteth-10 phosphate in an amount of 1.0-25% w/w;
- wherein the composition is a foam or cream.
3 more elements
Dependencies are inferred from the claim text.